Editas Medicine, Inc.

Editas Medicine Announces Third Quarter 2026 Results and Business Updates

Editas Medicine reported Q3 2026 results with a net loss of $23.4 million ($0.15 per share), improved from $25.1 million ($0.28) a year earlier, on collaboration revenue of $10.4 million, up from $7.5 million. The company received HREC approval and completed Australia's CTN process to start the Phase 1/2 Strive study of EDIT-401 in HeFH patients, with patient dosing on track this year, initial safety data in Q1 2027, and topline Part 1 results in 2H 2027. Preclinical data showed ≥90% LDL-C reduction maintained over 10 months in non-human primates. A second IND/CTA was accepted for BMS-986527, a CD70 allogeneic CAR-T therapy under the Bristol Myers Squibb collaboration, triggering a milestone payment to Editas. Cash of $190.2 million funds operations into the second half of 2028, through key Strive readouts.

•1h ago

Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia

Editas Medicine received Australian regulatory and ethics approval to initiate the Phase 1/2 Strive trial of EDIT-401, an in vivo gene editing medicine for heterozygous familial hypercholesterolemia, with the trial also submitted for review in New Zealand. EDIT-401 is designed to edit the LDLR gene to reduce LDL-cholesterol; preclinical data in non-human primates showed ~90% or greater reductions in LDL-C, Lp(a), and ApoB, with ~90% LDL-C reduction maintained over 10 months in an ongoing study. Patient dosing is expected to begin this year, with initial safety and tolerability data in the first quarter of 2027 and Part 1 topline safety and efficacy data later in 2027; new preclinical durability data will be presented at AHA Scientific Sessions on November 8, 2026.

•1mo ago

Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer

Editas Medicine appointed Dan Ory, M.D., as Chief Medical Officer, effective immediately, strengthening the executive team as the gene editing company advances its lead program toward the clinic. Dr. Ory brings more than 25 years of leadership in cardiovascular and genetic medicine, including CMO roles at Arbor Biotechnologies and Casma Therapeutics and two decades at Washington University School of Medicine researching cholesterol metabolism. He will oversee clinical development strategy and operations as EDIT-401, Editas' lead in vivo development candidate for the potential treatment of hyperlipidemia, moves toward clinical development, while supporting the broader pipeline. The appointment pairs deep cardiovascular and cholesterol-metabolism expertise directly with the company's most advanced program, reinforcing Editas' strategic focus on in vivo gene editing for serious diseases.

•2mo ago

Editas Medicine Announces Second Quarter 2026 Results and Business Updates

Editas Medicine reported a narrowed Q2 net loss of $0.15 per share, down from a $0.63 loss in the prior year, while revenue rose to $11.9 million driven by deferred revenue recognition. The company strengthened its balance sheet with $211.6 million in cash as of June 30, extending its runway into the second half of 2028 following a recent $125 million public offering. Operationally, Editas is on track to submit a Clinical Trial Notification for EDIT-401 this month, citing new preclinical data showing a single dose achieved ~90% mean reductions in LDL cholesterol in non-human primates.

•3mo ago

Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.

Editas Medicine appointed Dr. Patrick T. Ellinor to its Board of Directors effective August 6, 2026, while independent director Dr. Elliott Levy stepped down from the Board. Dr. Ellinor currently serves as Executive Director of the Mass General Brigham Heart and Vascular Institute and Director of the Cardiovascular Disease Initiative at the Broad Institute. His expertise is expected to support the company's strategy as it advances EDIT-401 for the potential treatment of hyperlipidemia and continues building its in vivo gene editing platform.

•3mo ago

Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress

Editas Medicine presented preclinical data for EDIT-401 at the European Atherosclerosis Society Congress, showing a single dose achieved ~90% mean reductions in LDL-C, Lp(a), and ApoB in non-human primates. The data supports the asset's potential as a best-in-class gene editing medicine for hyperlipidemia, with reductions highly correlated and driven by LDLR upregulation. The company received positive pre-IND feedback from the FDA and plans to submit a Clinical Trial Notification in Australia by mid-2026, targeting early human proof-of-concept data by year-end.

•5mo ago

Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting

Editas Medicine presented new preclinical data for EDIT-401, showing a ≥90% mean LDL-C reduction across all dose groups in non-human primates. The LDL-C lowering was rapid and durable, lasting through ~6 months with no adverse clinical observations at the therapeutically relevant dose (1.5 mg/kg). The data also supports the broader potential of Editas' in vivo gene upregulation platform, leveraging DNA large language prediction models to streamline development.

•5mo ago

Editas Medicine Announces First Quarter 2026 Results and Business Updates

Editas Medicine reported Q1 2026 financial results, significantly narrowing its net loss to $25.0 million ($0.26/share) from $76.1 million in the prior year, while maintaining a cash runway into Q3 2027. The company advanced its lead candidate EDIT-401, with preclinical data showing >90% mean LDL-C reduction and plans to initiate a first-in-human study for HeFH later this year. Additionally, the USPTO reaffirmed a prior patent decision in favor of the Broad Institute regarding CRISPR/Cas9 editing, supporting Editas' intellectual property position.

•6mo ago